Guidance Notes

GNT 68: Making Tax Digital for VAT

GNX 10: Transactions – Good Practice Part II

GNX 9: Transactions – Good Practice Part I

GNMA 7: Impact of Brexit on the regulatory approval process for medicines in the UK

GNES 8: The Importance of Learning Agility

GNL 36: Placing medical devices on the UK market after the end of Brexit transition

GNL 35: What the UK-EU Trade and Cooperation Agreement means for pharma and medical device companies

GNT 35: Tax Implications of Brexit on the Pharmaceutical Industry

GNL 33: Patents in the company lifecycle: M&A and joint ventures

GNES 7: The Good And Bad of Video Interviewing

GNX 8: The Divestment Challenge

GNT 67: Non-resident directors

GNMA 6: Impact of conditional approval and approval under exceptional circumstances on national pricing and reimbursement

GNL 34: Patents in the company lifecycle: IPO and divestment

GNES 6: The importance of direct approach (in executive search)

GNL 31: Open innovation

GNX 7: PharmaVentures Data Room Structure Guideline

GNT 66: Knowledge Intensive Companies

GNMA 5: Learning from previous NICE consultations

GNL 32: The importance of IP due diligence

GNMA 4: Cell and Gene Therapies – innovative contracting trends in Europe

GNMA 3: How can early access schemes support accelerated patient access in Europe?

GNMA 2: Top five reasons why products fail to achieve a positive NICE recommendation

GNMA 1: Improving access to orphan medicines

GNES 5: Creating a company culture that attracts and retains talent during and post-global pandemic

GNES 4: Attracting the right talent in the times of coronavirus – Job Description as a Talent Magnet

GNES 3: Can/should executive search help improve gender diversity?

GNES 2: Recruit for future-proof profiles

GNES 1: Differences in recruiting for a big pharma and a small biotech

GNT 68: Making Tax Digital for VAT

GNX 10: Transactions – Good Practice Part II

GNX 9: Transactions – Good Practice Part I

GNMA 7: Impact of Brexit on the regulatory approval process for medicines in the UK

GNES 8: The Importance of Learning Agility

GNL 36: Placing medical devices on the UK market after the end of Brexit transition

GNL 35: What the UK-EU Trade and Cooperation Agreement means for pharma and medical device companies

GNT 35: Tax Implications of Brexit on the Pharmaceutical Industry

GNL 33: Patents in the company lifecycle: M&A and joint ventures

GNES 7: The Good And Bad of Video Interviewing

GNX 8: The Divestment Challenge

GNMA 6: Impact of conditional approval and approval under exceptional circumstances on national pricing and reimbursement

GNL 34: Patents in the company lifecycle: IPO and divestment

GNES 6: The importance of direct approach (in executive search)

GNL 31: Open innovation

GNX 7: PharmaVentures Data Room Structure Guideline

GNT 66: Knowledge Intensive Companies

GNMA 5: Learning from previous NICE consultations

GNL 32: The importance of IP due diligence

GNMA 4: Cell and Gene Therapies – innovative contracting trends in Europe

GNMA 3: How can early access schemes support accelerated patient access in Europe?

GNMA 2: Top five reasons why products fail to achieve a positive NICE recommendation

GNMA 1: Improving access to orphan medicines

GNES 5: Creating a company culture that attracts and retains talent during and post-global pandemic

GNES 4: Attracting the right talent in the times of coronavirus – Job Description as a Talent Magnet

GNES 3: Can/should executive search help improve gender diversity?

GNES 2: Recruit for future-proof profiles

GNES 1: Differences in recruiting for a big pharma and a small biotech